Peptidoglycan

Longhorn Vaccines and Diagnostics Presents Targeted Vaccine Approach for Mycobacterium Tuberculosis with LHNVD-301

Retrieved on: 
Wednesday, November 15, 2023
Science, Veterinary, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Clinical Trials, Pandemic, Peptide, MTB, Lung, Safety, Peptidoglycan, The Union, Serum, PGN, Immunoglobulin G, Risk, Gram-positive bacteria, Epitope, Staphylococcus aureus, ELISA, Infection, Staphylococcus, Staphylococcus epidermidis, Vaccine, Mycobacterium tuberculosis, Bacillus subtilis, Cell wall, AMR, Conference, Streptococcus, Virus, Antibody, Bacilli, Mycobacterium smegmatis, Tuberculosis, Public, TB, ICR, Bacteria, Longhorn, MD

Longhorn Vaccines and Diagnostics , a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, today presented new data from an animal study of LHNVD-301, the company’s lead tuberculosis vaccine candidate.

Key Points: 
  • Longhorn Vaccines and Diagnostics , a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, today presented new data from an animal study of LHNVD-301, the company’s lead tuberculosis vaccine candidate.
  • The data showed that a mycobacterium tuberculosis (MTB) vaccine could generate broader protection against other pathogens susceptible to antimicrobial resistance (AMR).
  • LHNVD-301 is an unconjugated, peptide-based vaccine that combines a MTB heat shock protein epitope and a peptidoglycan (PGN) epitope.
  • It represents a novel approach that combats AMR, while targeting tuberculosis by combining multiple epitopes specific to MTB and common to gram-positive bacteria into a peptide vaccine.

Longhorn Vaccines and Diagnostics to Present Data on Mycobacterium Tuberculosis Vaccine Candidate, LHNVD-301, at The Union World Conference on Lung Health 2023

Retrieved on: 
Thursday, November 2, 2023
Science, Other Science, Research, Medical Supplies, General Health, Health, Infectious Diseases, Other Health, The Union, Vaccine, TB, Gram-positive bacteria, International Workshop on Lung Health, Conference, Union, Lung, Public, Mycobacterium tuberculosis, Tuberculosis, Drug resistance, Longhorn, Peptidoglycan

Longhorn Vaccines and Diagnostics , a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, will present new data from an animal study of LHNVD-301, the company’s tuberculosis vaccine candidate, at The Union World Conference on Lung Health 2023.

Key Points: 
  • Longhorn Vaccines and Diagnostics , a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, will present new data from an animal study of LHNVD-301, the company’s tuberculosis vaccine candidate, at The Union World Conference on Lung Health 2023.
  • The ePoster will be presented as a part of TBScience 2023, a dedicated event focused on basic and translational tuberculosis (TB) research.
  • LHNVD-301 is an unconjugated, peptide-based vaccine that combines Mycobacterium tuberculosis heat shock protein and Peptidoglycan to generate broad reactive antibodies.
  • ePoster Session Title: TB within the Global AMR fight: preventing drug resistance
    Over the last 53 years, the Union World Conference on Lung Health has presented the latest scientific research in all aspects of lung health, including implementation of evidence-based health policies and decisions.

Bay Area Lyme Foundation Celebrates Department of Defense CDMRP Tick-borne Disease Awardees

Retrieved on: 
Thursday, March 23, 2023
Columbia University, Tufts University, Duke University, Biobank, Notifiable disease, Doctor of Pharmacy, Virginia Tech, Therapy, Lyme disease, Babesiosis, Frontiers, Gastrointestinal tract, Infection, COVID-19, DNA sequencing, AGS, Immunoglobulin M, PCR, MBA, Research, Immunoglobulin A, Tick, Antibody, Peptidoglycan, Veteran, Tick-Borne Disease Alliance, Johns Hopkins University, Blood transfusion, Patient, Risk, Blood, Immunoglobulin G, DVM, NIH, MBI, Skin, Vaccine, Microbiology, Doctor of Philosophy, MD

PORTOLA VALLEY, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation , a leading sponsor of Lyme disease research in the US, announces that two projects it has previously funded have now received Department of Defense Congressionally Directed Medical Research Programs (CDMRP) Tick-Borne Disease awards.

Key Points: 
  • PORTOLA VALLEY, Calif., March 23, 2023 (GLOBE NEWSWIRE) -- Bay Area Lyme Foundation , a leading sponsor of Lyme disease research in the US, announces that two projects it has previously funded have now received Department of Defense Congressionally Directed Medical Research Programs (CDMRP) Tick-Borne Disease awards.
  • Three of the six recently announced CDMRP awardees will be using biological samples from Bay Area Lyme Foundation’s Lyme Disease Biobank to enable their research into diagnostics and therapeutics for tick-borne diseases, including Lyme disease—which infects half a million people each year.
  • Peter Gwynne, research assistant professor in Hu's lab, was a Bay Area Lyme Foundation ELA winner in 2022 and has used samples from the Lyme Disease Biobank.
  • Jutras was a Bay Area Lyme Foundation ELA winner in 2021 and his lab will be using samples from the Lyme Biobank to validate their novel diagnostics.

Sigyn Therapeutics Announces Second Quarter 2022 Financial Results

Retrieved on: 
Monday, August 15, 2022
Death, Regulation of tobacco by the U.S. Food and Drug Administration, U.S. Securities and Exchange Commission, Securities Act of 1933, United, IL-6, Pneumonia, Inflammation, CEO, GLOBE, CA, Technology, Securities Exchange Act of 1934, Coronavirus Scientific Advisory Board (Turkey), Security (finance), Annual report, Interleukin, Liver transplantation, Patient, Therapy, COVID-19, Company, Infection, SAN, Neurology, TNF, CPA, Toxin (comics), Chronic kidney disease, Risk, Nephrology, OTCQB, University, MBA, Lipopolysaccharide, Investor, Peptidoglycan, Food, Global health, Pharmaceutical industry

SAN DIEGO, CA, Aug. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (OTCQB: SIGY), adevelopment-stage company focused on the creation of therapeutic solutions that address unmet needs in global health, today announces its financial results for the second quarter ended June 30, 2022 and provides an update on recent corporate developments.

Key Points: 
  • SAN DIEGO, CA, Aug. 15, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (OTCQB: SIGY), adevelopment-stage company focused on the creation of therapeutic solutions that address unmet needs in global health, today announces its financial results for the second quarter ended June 30, 2022 and provides an update on recent corporate developments.
  • We continue to take meaningful steps toward our goal to advance Sigyn Therapy into human clinical studies, commented Jim Joyce, co-founder and CEO of Sigyn Therapeutics.
  • For complete financial results, please see Sigyn Therapeutics filings at www.sec.gov ,and on the Company's website at www.SigynTherapeutics.com under "Financial Info" in the Investors section.
  • Sigyn Therapeutics is a development-stage company focused on the creation of therapeutic solutions that address unmet needs in global health.

Sigyn Therapeutics™ Announces Completion of Animal Studies

Retrieved on: 
Wednesday, February 23, 2022
GLOBE, Observation, United States v. 50 Acres of Land, Achievement, Death, Risk, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Securities Exchange Act of 1934, University, Inflammation, Security (finance), Septic shock, Annual report, IACUC, CRRT, Therapy, Cytokine, Innovation, Company, Ammonia, Hemofiltration, Hepatic encephalopathy, CA, IL-6, U.S. Securities and Exchange Commission, Community-acquired pneumonia, Food, Adult, Blood, Institutional Animal Care and Use Committee, Severe acute respiratory syndrome coronavirus 2, Sepsis, Infection, Global health, FDA, IDE, SAN, Securities Act of 1933, TNF, IBT, Technology, Drug Quality and Security Act, Bioterrorism, Seminal vesicles, CEO, OTC Markets Group, Hospital, Peptidoglycan, Pharmaceutical industry, Medical device, Vaccine

SAN DIEGO, CA, Feb. 23, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTC Markets:“SIGY”), a medical technology company focused on the treatment of pathogen-associated conditions that induce sepsis, today reported the successful completion of an in vivo animal study that demonstrated Sigyn Therapy to be safe and well tolerated.

Key Points: 
  • Overall, Sigyn Therapy was well tolerated by all eight animal subjects and no serious adverse events were reported in any treated animal.
  • Sigyn Therapeutics is a medical technology company focused on the treatment of pathogen-associated conditions that precipitate sepsis, the leading cause of hospital deaths worldwide.
  • Beyond these broad-spectrum capabilities, animal studies have demonstrated the safe administration of Sigyn Therapy.
  • This information in this press release contains forward-looking statements of Sigyn Therapeutics, Inc. (Sigyn) that involve substantial risks and uncertainties.

Global Lyme Alliance Funds $13 Million in Lyme Disease Research to Date and Announces Exciting New Grants

Retrieved on: 
Friday, January 21, 2022
Coronavirus Scientific Advisory Board (Turkey), Association, Doctor of Philosophy, Biofilm, Research, Patient, PTLD, NIH, Central nervous system, Korea Disease Control and Prevention Agency, Neuroborreliosis, Inflammation, Center, University, Tick-Borne Disease Alliance, Intention, University of Kentucky, Peptidoglycan, Diagnosis, Chronic Lyme disease, University of Guelph, Joint, University of North Dakota, Lists of diseases, Health, Neuroinflammation, GLA, Bacteria, Tissue, Degenerative disease, LNB, University of Central Florida, Heart, Education, Immunity, Central Florida, Formation, Brain, Infection, Physician, Awareness, Pharmaceutical industry, Vaccine, Dietary supplement, Lyme disease

GLA received fifty-eight Letters of Intent, describing some of the most exciting and cutting-edge research ideas we have ever considered for funding.

Key Points: 
  • GLA received fifty-eight Letters of Intent, describing some of the most exciting and cutting-edge research ideas we have ever considered for funding.
  • Mollie Jewett, Ph.D., University of Central Florida, " Lyme iDS: An Innovative Point-of-Care System for Reliable Diagnosis of Lyme Disease. "
  • Dr. Jutras discovered that a structural protein fromBorrelia burgdorferi(the bacteria that causes Lyme disease) could trigger a strong inflammatory response in patients with post-treatment Lyme disease (PTLD).
  • Lyme neuroborreliosis (LNB), also known as neurological Lyme disease, occurs in 1015% of Lyme disease cases.

Sigyn Therapeutics Reports the Successful Completion of a Study to Address Gram-Positive Bacterial Toxins Associated with Sepsis

Retrieved on: 
Wednesday, December 1, 2021
CRRT, IDE, Hepatic encephalopathy, CEO, Blood, Septic shock, MRSA, Industry, Sepsis, Death, Company, Hospital, OTC Markets Group, Private Securities Litigation Reform Act, Virus, IL-6, Inflammation, Ammonia, COVID-19, Bioterrorism, Cytokine, United States v. 50 Acres of Land, Peptidoglycan, LTA, Community-acquired pneumonia, Risk, GLOBE, Adult, FDA, In vitro, PG, Infection, CA, Therapy, Failure, TNF, Hemofiltration, Vaccine, Pharmaceutical industry

SAN DIEGO, CA, Dec. 01, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Sigyn Therapeutics, Inc. (OTC Markets: SIGY), a medical technology company focused on the treatment of pathogen-associated indications that precipitate sepsis, today announced that preclinical invitro studies have validated the ability of Sigyn Therapy to deplete the presence of gram-positive bacterial toxins from human blood plasma.

Key Points: 
  • The invitro clearance of both targets was rapid, with an ~50% reduction of PG at one hour and a ~70% reduction of LTA at two hours.
  • In addition to being potent activators of sepsis, there is a heightened interest in gram-positive pathogens based on the continuing emergence of drug resistant species, including antibiotic-resistant Staphylococcus aureus (MRSA).
  • Sigyn Therapeutics is a medical technology company focused on the treatment of pathogen-associated indications that precipitate sepsis, the #1 cause of hospital deaths worldwide.
  • This press release contains forward-looking statements of Sigyn Therapeutics, Inc. (Sigyn) that involve substantial risks and uncertainties.